<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118687</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#170398</org_study_id>
    <nct_id>NCT03118687</nct_id>
  </id_info>
  <brief_title>Human Immunome Program</brief_title>
  <acronym>HIP</acronym>
  <official_title>Human Immunome Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Vaccines Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Human Immunome Program is a large-scale, open-source effort seeking to fill a major gap&#xD;
      in our knowledge of the immune system. The power of the immune system to fight disease lies&#xD;
      in its ability recognize and adapt to an astonishing range of threats from viruses, parasites&#xD;
      and bacteria to cancer cells. Underlying this ability is a vast but specific set of genes and&#xD;
      molecular structures known as the human immunome, or the &quot;parts list&quot; of the immune system.&#xD;
      This study aims to decipher the genetic sequences that make up this part list and link it to&#xD;
      information about a person's microbiome composition and characteristics such as health&#xD;
      history, race, and demographics over time. This information, made freely available to the&#xD;
      public for use in research in de-identified form, will allow investigators to answer a wide&#xD;
      variety of different questions about immune system function. This could transform how we&#xD;
      diagnose, prevent and treat disease though the identification of new biomarkers while&#xD;
      enabling highly targeted, computationally designed vaccines and therapies that reduce time&#xD;
      and risk of product development.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The entire expressed B and T cell receptor repertoire (&quot;Immunome&quot;) of the human immune system</measure>
    <time_frame>10 years</time_frame>
    <description>The B and T cell receptor repertoire will be sequenced. The sequencing will continue until no new unique sequences appear.</description>
  </primary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biospecimen and survey collection</intervention_name>
    <description>Blood, microbiota, surveys/questionnaires, electronic medical records.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Peripheral blood mononuclear cell (PBMCs)&#xD;
&#xD;
        -  Microbiome (stool, tongue, skin swabs)(optional)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adult volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female volunteers between the ages of 18 - 49 years of age at the&#xD;
             time of first enrollment.&#xD;
&#xD;
          -  Ability to comply: Participant willing and able to comply with the requirements of the&#xD;
             protocol.&#xD;
&#xD;
          -  Consent: Participants who have given informed consent for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Reason for exclusion throughout the entire study period:&#xD;
&#xD;
          -  History of severe anemia requiring blood transfusion or current Hemoglobin &lt; 10g/dL.&#xD;
&#xD;
          -  Currently pregnant or pregnancy within 6 months.&#xD;
&#xD;
          -  Current participation in another study resulting in blood collection which exceeds 550&#xD;
             ml in an 8 week period or occurs more frequently than 2 times per week.&#xD;
&#xD;
          -  Temperature &gt;101.4F&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, might interfere with study&#xD;
             objectives.&#xD;
&#xD;
          -  Any reason which, in the opinion of the investigator, adds additional risk to the&#xD;
             patient.&#xD;
&#xD;
        Reason for exclusion in year 0 but not in year 1-9:&#xD;
&#xD;
          -  History of known HIV infection or treatment.&#xD;
&#xD;
          -  Immunosuppressive disease or use of systemic immunosuppressive therapy using drugs or&#xD;
             cytotoxic agents including prednisone (IV, oral or inhaled) less than 6 months ago.&#xD;
&#xD;
          -  History of diabetes mellitus -or a glucose (on CMP) â‰¥200 mg/dL.&#xD;
&#xD;
          -  History of cancer including skin cancer.&#xD;
&#xD;
          -  History of autoimmune disorders including but not limited to: Ulcerative colitis,&#xD;
             Crohn's, Inflammatory Bowel Disease, Rheumatoid Arthritis, Scleroderma, Systemic lupus&#xD;
             Erythematosus, Mixed Connective Tissue Disease, Graves, Autoimmune Thyroiditis,&#xD;
             Hashimoto's Thyroiditis, Psoriasis, Multiple Sclerosis, Guillain-Barre Syndrome,&#xD;
             Chronic Inflammatory demyelinating polyneuropathy, Myasthenia Gravis, Vasculitis,&#xD;
             Alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis,&#xD;
             idiopathic thrombocytopenic purpura, pemphigus, pernicious anemia, polyarteritis&#xD;
             nodosa, polymyositis, Sjogren's Syndrome, Wegener's&#xD;
&#xD;
          -  Severe obesity = (BMI &gt;40 kg/m2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James E Crowe Jr., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://humanvaccinesproject.org</url>
    <description>The Human Vaccines Project is the parent project to the Human Immunome Program</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>James E. Crowe, Jr.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Immune system</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

